Asset Details
Do you wish to reserve the book?
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Do you wish to request the book?
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013
Overview
In this multicenter trial, the oral factor Xa inhibitor apixaban was compared with enoxaparin and warfarin for the treatment of acute venous thromboembolism. Apixaban was noninferior to enoxaparin and warfarin with respect to efficacy and superior with respect to safety.
Venous thromboembolism, with an annual incidence of 1 to 2 cases per 1000 persons in the general population, is the third most common cause of vascular death after myocardial infarction and stroke.
1
Conventional treatment consists of a parenteral anticoagulant, such as enoxaparin, for at least 5 days, and warfarin begun during this time and continued for at least 3 months.
2
Although effective, this regimen presents a challenge because enoxaparin requires daily subcutaneous injections, and warfarin therapy requires coagulation monitoring and dose adjustment.
Apixaban is an oral factor Xa inhibitor with a rapid onset of action and predictable pharmacokinetics that allow . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Anticoagulants - administration & dosage
/ Anticoagulants - adverse effects
/ Anticoagulants - therapeutic use
/ Biological and medical sciences
/ Bleeding
/ Enoxaparin - adverse effects
/ Enoxaparin - therapeutic use
/ Female
/ Hemorrhage - chemically induced
/ Humans
/ Male
/ Patients
/ Pyrazoles - administration & dosage
/ Pyridones - administration & dosage
/ Venous Thromboembolism - drug therapy
/ Warfarin
